Experienced in Merkel Cell Carcinoma

Dr. Robert C. Doebele

Oncology
12605 E 16th Ave, 
Aurora, CO 
Clinical Trials:Currently Recruiting for 3 Trials
Experienced in Merkel Cell Carcinoma
12605 E 16th Ave, 
Aurora, CO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Robert Doebele is an Oncologist in Aurora, Colorado. Dr. Doebele is rated as an Experienced provider by MediFind in the treatment of Merkel Cell Carcinoma. His top areas of expertise are Lung Cancer, Lung Adenocarcinoma, Non-Small Cell Lung Cancer (NSCLC), and EGFR Positive Lung Cancer.

His clinical research consists of co-authoring 154 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Merkel Cell Carcinoma.

Specialties
Oncology
Licenses
Internal Medicine in CO
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

12605 E 16th Ave, Aurora, CO 80045

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung and Other Thoracic Cancers
Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung and Other Thoracic Cancers
Enrollment Status: Recruiting
Publish Date: August 06, 2025
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Enrollment Status: Recruiting
Publish Date: July 10, 2025
Intervention Type: Drug
Study Drug: Repotrectinib
Study Phase: Phase 1/Phase 2
Early Rebiopsy to Identify Mechanisms and Biomarkers of Tumor Cell Survival Following Systemic Therapy for Lung Cancer
Early Rebiopsy to Identify Mechanisms and Biomarkers of Tumor Cell Survival Following Systemic Therapy for Lung Cancer
Enrollment Status: Recruiting
Publish Date: February 06, 2025
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination With Nivolumab in Adult and Adolescent Patients 12 Years and Older With Advanced Solid Tumors
A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination With Nivolumab in Adult and Adolescent Patients 12 Years and Older With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Biological
Study Drug: CAB-AXL-ADC
Study Phase: Phase 1/Phase 2
A Phase II Study to Evaluate Neoadjuvant Osimertinib Therapy in Patients With Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer
A Phase II Study to Evaluate Neoadjuvant Osimertinib Therapy in Patients With Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 31, 2025
Intervention Type: Drug, Procedure
Study Drug: Osimertinib
Study Phase: Phase 2
A Phase 1/2 Study of TPX-0046, A Novel Oral RET/SRC Inhibitor in Adult Subjects With Advanced/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations
A Phase 1/2 Study of TPX-0046, A Novel Oral RET/SRC Inhibitor in Adult Subjects With Advanced/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations
Enrollment Status: Terminated
Publish Date: June 13, 2024
Intervention Type: Drug
Study Drug: TPX-0046
Study Phase: Phase 1/Phase 2
A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201 Added to Pembrolizumab in Subjects With Non-Small Cell Lung Cancer With High PD-L1 Expression
A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201 Added to Pembrolizumab in Subjects With Non-Small Cell Lung Cancer With High PD-L1 Expression
Enrollment Status: Terminated
Publish Date: August 08, 2023
Intervention Type: Biological
Study Drug: GRN-1201+Pembrolizumab
Study Phase: Phase 2
A Phase II Trial to Evaluate Crizotinib in the Neoadjuvant Setting in Patients With Surgically Resectable, ALK, ROS1, or MET-oncogene Positive Non-small Cell Lung Cancer
A Phase II Trial to Evaluate Crizotinib in the Neoadjuvant Setting in Patients With Surgically Resectable, ALK, ROS1, or MET-oncogene Positive Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: February 11, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
Enrollment Status: Completed
Publish Date: August 30, 2021
Intervention Type: Drug
Study Drugs: Ciforadenant, Ciforadenant+Atezolizumab
Study Phase: Phase 1
View 7 Less Clinical Trials

154 Total Publications

EGFR suppression and drug-induced potentiation are widespread features of oncogenic RTK fusions.
EGFR suppression and drug-induced potentiation are widespread features of oncogenic RTK fusions.
Journal: bioRxiv : the preprint server for biology
Published: December 03, 2025
Similar Doctors
Elite in Merkel Cell Carcinoma
Dr. Karl Lewis
Hematology | Oncology
Elite in Merkel Cell Carcinoma
Dr. Karl Lewis
Hematology | Oncology
12605 E 16th Ave, 
Aurora, CO 
 (0.1 miles away)
720-848-0000
Languages Spoken:
English
See accepted insurances

Karl Lewis is a Hematologist and an Oncologist in Aurora, Colorado. Dr. Lewis is rated as a Distinguished provider by MediFind in the treatment of Merkel Cell Carcinoma. His top areas of expertise are Melanoma, Basal Cell Skin Cancer, Merkel Cell Carcinoma, and Neuroendocrine Tumor.

Distinguished in Merkel Cell Carcinoma
Dr. Theresa Medina
Hematology | Oncology
Distinguished in Merkel Cell Carcinoma
Dr. Theresa Medina
Hematology | Oncology

University Physicians Incorporated

13123 E 16th Ave, 
Aurora, CO 
 (0.4 miles away)
720-777-1234
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Theresa Medina is a Hematologist and an Oncologist in Aurora, Colorado. Dr. Medina is rated as a Distinguished provider by MediFind in the treatment of Merkel Cell Carcinoma. Her top areas of expertise are Melanoma, Merkel Cell Carcinoma, Squamous Cell Skin Carcinoma, and Metastatic Uveal Melanoma.

Advanced in Merkel Cell Carcinoma
Dr. Ling Ma
Hematology Oncology | Hematology | Oncology
Advanced in Merkel Cell Carcinoma
Dr. Ling Ma
Hematology Oncology | Hematology | Oncology

Rocky Mountain Cancer Centers Llp

8820 Huron St, 
Thornton, CO 
 (11.4 miles away)
303-386-7622
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ling Ma is a Hematologist Oncology specialist and a Hematologist in Thornton, Colorado. Dr. Ma is rated as a Distinguished provider by MediFind in the treatment of Merkel Cell Carcinoma. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Agranulocytosis, and Chronic Familial Neutropenia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Doebele's expertise for a condition
ConditionClose
View All 12 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile